- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Leverkusen, September 8, 2016 – Bayer is once again included in the Dow Jones Sustainability World Index (DJSI World). Bayer is thus listed in this sustainability index for the 17th time in succession since its inception in 1999, confirming its leading international standing as a pharmaceutical and chemical company employing sustainable business practices.
“We are delighted by our renewed listing in this renowned sustainability index,” said Dr. Hartmut Klusik, member of the Bayer Board of Management responsible for Human Resources, Technology and Sustainability. “It is part of our Group strategy to integrate sustainability into our daily work routines and to combine commercial success with the fulfillment of social and ecological demands,” added Dr. Klusik. “The sustainable alignment of our entrepreneurial activities is playing an essential role in our Group’s future viability.”
The Swiss rating agency RobecoSAM assessed almost 2000 of the world’s largest listed companies on behalf of the index provider S&P Dow Jones Indices according to the “best-in-class” principle: the DJSI World lists the top 10 percent of companies in a particular sector on the basis of an extensive set of criteria. In its sector, Bayer was rated particularly highly in the areas of supplier management, staff development and respect of human rights.
The DJSI World serves as a guide to institutional investors who place particular value on sustainability for their investment strategy.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.